SEC Filing Summary: AVI BioPharma, Inc. (Form 10-Q)
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for AVI BioPharma, Inc., a development-stage biopharmaceutical company, for the period ended September 30, 2007. The company focuses on the development of antisense therapeutics. The financial statements for the prior year periods (2006) have been restated due to the reclassification of certain warrants from equity to liabilities in accordance with EITF 00-19. The company has incurred cumulative losses of approximately $222 million since its inception in 1980 and has not generated material revenue from product sales.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Balance Sheet (Sep 30, 2007) |
|---|---|---|---|
| Revenues (License fees, grants, contracts) | $2,911,406 | $5,798,872 | N/A |
| Net Loss | $(7,034,944) | $(23,040,531) | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.43) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,861,272 |
| Short-term Securities (Available-for-sale) | N/A | N/A | $10,188,487 |
| Total Current Assets | N/A | N/A | $16,754,113 |
| Total Current Liabilities | N/A | N/A | $9,550,330 |
| Long-term Debt (Current + Non-current) | N/A | N/A | $2,159,058 |
| Warrant Liability | N/A | N/A | $1,642,246 |
| Accumulated Deficit | N/A | N/A | $(222,230,361) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased significantly to $2.91 million for the quarter (from $13,252 in Q3 2006) and $5.80 million for the nine months (from $97,772 in 2006). This was driven primarily by research contract revenues from the Department of Defense (DTRA) and other defense-related programs.
- Operating Expenses: Total operating expenses rose to $11.42 million for the quarter and $33.24 million for the nine months. Research and Development (R&D) expenses increased due to government contract expensing ($2.13M in Q3) and costs for manufacturing GMP subunits ($1.87M in Q3).
- Executive Compensation: General and Administrative (G&A) expenses increased due to a Separation and Release Agreement with the former CEO, resulting in $1.62 million in compensation costs (including $1.06 million in stock-based compensation) recognized in Q1 2007.
- Non-Cash Gains: The company recorded a non-cash gain on warrant liability of $1.30 million for the quarter and $3.55 million for the nine months, reducing the net loss. This gain fluctuates with the company's stock price.
- Liquidity: Cash and cash equivalents decreased from $20.16 million at year-end 2006 to $3.86 million at September 30, 2007, primarily due to cash used in operating activities ($17.35 million) and investing activities.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes the company has sufficient cash to fund operations through the first quarter of 2008, excluding future receipts from existing government contracts. Additional financing will be required to maintain operations beyond that point.
- Expenditure Guidance: For 2007, the company expects expenditures for operations (net of government funding) to be approximately $24 million to $26 million. This could increase if additional collaborative efforts are undertaken.
- Government Contracts: The company relies heavily on government funding, including a two-year $28 million contract with the Defense Threat Reduction Agency (DTRA) for antiviral development and an $11 million allocation for defense-related programs.
- Management Changes: The former CEO resigned in March 2007. K. Michael Forrest was appointed Interim CEO. The company is searching for a permanent replacement, and failure to do so could adversely affect R&D efforts.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2007. A material weakness was identified regarding the accounting treatment of derivative financial instruments (warrants), leading to the restatement of prior financial statements.
- Subsequent Events: In October 2007, the company received a $2.45 million research grant from Charley's Fund for Duchenne muscular dystrophy research and obtained a $4.5 million short-term loan secured by Certificates of Deposit.
Investor Verification Checklist
- Restatement Impact: Verify the full extent of the financial restatement regarding warrant liability classification and its effect on historical equity and net loss figures.
- Cash Runway: Confirm the company's ability to secure additional funding before the first quarter of 2008 to avoid curtailment of clinical programs.
- Government Contract Reliance: Assess the risk associated with the heavy reliance on DTRA and other government contracts for revenue, including the timing of future billings.
- CEO Transition: Monitor the progress of the search for a permanent CEO and the potential impact on strategic direction and R&D execution.
- Internal Control Remediation: Review the effectiveness of the remediation plan implemented to address the material weakness in internal controls over financial reporting.